Dr. Fuad S Farah, M.D. FAAD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1000 E Genesee St, Suite 601, Syracuse, NY 13210 Phone: 315-422-8331 Fax: 315-422-3129 |
Dr. Joyce B Farah, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 1000 E Genesee St, Suite 601, Syracuse, NY 13210 Phone: 315-422-8331 Fax: 315-422-3129 |
Dr. Ibrahim Ahmad Tangoren, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2949 Erie Boulevard East, Syracuse, NY 13224 Phone: 315-579-9037 Fax: 315-424-1779 |
Dr. Ramsay S Farah, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 1000 E Genesee St, Suite 601, Syracuse, NY 13210 Phone: 315-422-8331 Fax: 315-422-3129 |
Dr. Jon Curtis Lochner, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4900 Broad Road, Suite 4p, Syracuse, NY 13215 Phone: 315-492-5727 Fax: 315-492-5003 |
Karen Lee Quint, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1000 East Genesse St, Ste 100, Syracuse, NY 13210 Phone: 315-701-0070 Fax: 315-701-0075 |
Dr. Lewis M Dubroff, M.D., PH.D. Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 475 Irving Ave, Suite 314, Syracuse, NY 13210 Phone: 315-471-3384 Fax: 315-471-3394 |
News Archive
The language that doctors use with low-income, rural patients can help determine whether these patients agree to participate in clinical trials testing new cancer treatments, a new study found.
The Entrepreneur Lab just announced Gerard White, CEO of Clearwave Corporation, as a One to Watch Entrepreneur in Atlanta. The Entrepreneur Lab was founded in order to highlight Atlanta business leaders who motivate and transform companies in Atlanta.
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.
Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.
› Verified 9 days ago